1. Cancer-causingBRCA2missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance
- Author
-
Robert Mahen, Benjamin A. Hall, David Shorthouse, Miyoung Lee, and Ashok R. Venkitaraman
- Subjects
Proteasome Endopeptidase Complex ,DNA Repair ,endocrine system diseases ,AcademicSubjects/SCI00010 ,DNA repair ,Mutant ,Mutation, Missense ,Breast Neoplasms ,Genome Integrity, Repair and Replication ,Biology ,medicine.disease_cause ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Genetics ,medicine ,Humans ,Missense mutation ,Homologous Recombination ,skin and connective tissue diseases ,030304 developmental biology ,BRCA2 Protein ,Ovarian Neoplasms ,0303 health sciences ,Mutation ,Wild type ,female genital diseases and pregnancy complications ,Cell biology ,HEK293 Cells ,Recombinant DNA ,Female ,030217 neurology & neurosurgery ,Intracellular ,HeLa Cells ,Protein Binding - Abstract
Cancer-causing missense mutations in the 3418 amino acid BRCA2 breast and ovarian cancer suppressor protein frequently affect a short (∼340 residue) segment in its carboxyl-terminal domain (DBD). Here, we identify a shared molecular mechanism underlying their pathogenicity. Pathogenic BRCA2 missense mutations cluster in the DBD’s helical domain (HD) and OB1-fold motifs, which engage the partner protein DSS1. Pathogenic - but not benign – DBD mutations weaken or abolish DSS1-BRCA2 assembly, provoking mutant BRCA2 oligomers that are excluded from the cell nucleus, and disable DNA repair by homologous DNA recombination (HDR). DSS1 inhibits the intracellular oligomerization of wildtype, but not mutant, forms of BRCA2. Remarkably, DSS1 expression corrects defective HDR in cells bearing pathogenic BRCA2 missense mutants with weakened, but not absent, DSS1 binding. Our findings identify a DSS1-mediated intracellular protein assembly mechanism that is disrupted by cancer-causing BRCA2 missense mutations, and suggest an approach for its therapeutic correction., Graphical Abstract Graphical AbstractCancer-causing mutations in the BRCA2 DBD impair DSS1 binding, provoking intracellular oligomerization and cytosolic mis-localization of the mutant BRCA2, and defective homologous recombination. These defects are reversed by DSS1 overexpression, for certain DBD mutants that retain small amounts of DSS1 binding.
- Published
- 2021
- Full Text
- View/download PDF